semaglutide mdv Minnesota doctor says FDA weight-loss drug cutoff is 'devastating' for patients Wegovy® Semaglutide 2.4 mg /

Bone mineral density and lean mass gains were observed in aged rat models, consistent with expected GH/IGF-1 axis activity

Future studies may look to examine a role for modalities such as point-of-care gastric ultrasound to determine residual gastric content prior to induction of anesthesia in these patients

Of the 43,620 new users of semaglutide in the database, 56% were aged 50 to 69 years and 61% were female

Other GLP-1 agonists: stacking another GLP-1 agonist on top of retatrutide+cagrilintide is rarely described in conservative community references the GLP-1 axis is already saturated

Random dose changes without guidance can lead to weight regain, unpredictable side effects, and wasted medication

Read more Osteoporosis: Symptoms, Causes, DEXA Screening, and Treatment What Your Doctor Wants You to Know in 2026 Osteoporosis quietly weakens bones for years without a single symptom and nearly 1 in 2 women over 50 will break a bone because of it